Literature DB >> 22214762

A functional cooperativity between Aurora A kinase and LIM kinase1: implication in the mitotic process.

Lisa Ritchey1, Richard Ottman, Michael Roumanos, Ratna Chakrabarti.   

Abstract

Aurora kinase A (Aur-A), a mitotic kinase, regulates initiation of mitosis through centrosome separation and proper assembly of bipolar spindles. LIM kinase 1 (LIMK1), a modulator of actin and microtubule dynamics, is involved in the mitotic process through inactivating phosphorylation of cofilin. Phosphorylated LIMK1 is recruited to the centrosomes during early prophase, where it colocalizes with γ-tubulin. Here, we report a novel functional cooperativity between Aur-A and LIMK1 through mutual phosphorylation. LIMK1 is recruited to the centrosomes during early prophase and then to the spindle poles, where it colocalizes with Aur-A. Aur-A physically associates with LIMK1 and activates it through phosphorylation, which is important for its centrosomal and spindle pole localization. Aur-A also acts as a substrate of LIMK1, and the function of LIMK1 is important for its specific localization and regulation of spindle morphology. Taken together, the novel molecular interaction between these two kinases and their regulatory roles on one another's function may provide new insight on the role of Aur-A in manipulation of actin and microtubular structures during spindle formation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22214762      PMCID: PMC3293380          DOI: 10.4161/cc.11.2.18734

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  68 in total

1.  Validation of a flow cytometry based G(2)M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition.

Authors:  Jose Estevam; Hadi Danaee; Ray Liu; Jeffrey Ecsedy; William L Trepicchio; Timothy Wyant
Journal:  J Immunol Methods       Date:  2010-09-29       Impact factor: 2.303

2.  LATS2-Ajuba complex regulates gamma-tubulin recruitment to centrosomes and spindle organization during mitosis.

Authors:  Yoshinori Abe; Miho Ohsugi; Keiko Haraguchi; Jiro Fujimoto; Tadashi Yamamoto
Journal:  FEBS Lett       Date:  2006-01-09       Impact factor: 4.124

3.  Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237.

Authors:  Dominic A Sloane; Michael Z Trikic; Matthew L H Chu; Maria B A C Lamers; Clive S Mason; Ilka Mueller; Wendy J Savory; David H Williams; Patrick A Eyers
Journal:  ACS Chem Biol       Date:  2010-06-18       Impact factor: 5.100

4.  Aurora-A expression, hormone receptor status and clinical outcome in hormone related cancers.

Authors:  Kakoli Das; Pia Donna Nitullano Lorena; Lai Kuan Ng; Liang Shen; Diana Lim; Woei Yun Siow; Kothandaraman Narasimhan; Ming Teh; Mahesh Choolani; Thomas C Putti; Manuel Salto-Tellez
Journal:  Pathology       Date:  2010       Impact factor: 5.306

5.  Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

Authors:  Bhavya Rao; Ingeborg M M van Leeuwen; Maureen Higgins; Johanna Campbel; Alastair M Thompson; David P Lane; Sonia Lain
Journal:  Oncotarget       Date:  2010-11

Review 6.  Aurora kinases as anticancer drug targets.

Authors:  Oliver Gautschi; Jim Heighway; Philip C Mack; Phillip R Purnell; Primo N Lara; David R Gandara
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

7.  Astrin regulates Aurora-A localization.

Authors:  Jian Du; Sandra Jablonski; Tim J Yen; Gregory J Hannon
Journal:  Biochem Biophys Res Commun       Date:  2008-03-24       Impact factor: 3.575

8.  Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization.

Authors:  N Yang; O Higuchi; K Ohashi; K Nagata; A Wada; K Kangawa; E Nishida; K Mizuno
Journal:  Nature       Date:  1998-06-25       Impact factor: 49.962

9.  TACC1-chTOG-Aurora A protein complex in breast cancer.

Authors:  Nathalie Conte; Bénédicte Delaval; Christophe Ginestier; Alexia Ferrand; Daniel Isnardon; Christian Larroque; Claude Prigent; Bertrand Séraphin; Jocelyne Jacquemier; Daniel Birnbaum
Journal:  Oncogene       Date:  2003-11-06       Impact factor: 9.867

10.  Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck.

Authors:  Alexander Hoellein; Anja Pickhard; Fabienne von Keitz; Stephanie Schoeffmann; Guido Piontek; Martina Rudelius; Anja Baumgart; Stefan Wagenpfeil; Christian Peschel; Tobias Dechow; Henning Bier; Ulrich Keller
Journal:  Oncotarget       Date:  2011-08
View more
  18 in total

1.  Phosphorylation of CHO1 by Lats1/2 regulates the centrosomal activation of LIMK1 during cytokinesis.

Authors:  Ayumi Okamoto; Norikazu Yabuta; Satomi Mukai; Kosuke Torigata; Hiroshi Nojima
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 2.  Issues in interpreting the in vivo activity of Aurora-A.

Authors:  Elena Shagisultanova; Roland L Dunbrack; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2014-11-11       Impact factor: 6.902

3.  Aurora A kinase modulates actin cytoskeleton through phosphorylation of Cofilin: Implication in the mitotic process.

Authors:  Lisa Ritchey; Ratna Chakrabarti
Journal:  Biochim Biophys Acta       Date:  2014-08-01

Review 4.  The Aurora kinase inhibitors in cancer research and therapy.

Authors:  Jonas Cicenas
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-01       Impact factor: 4.553

Review 5.  Aurora A kinase (AURKA) in normal and pathological cell division.

Authors:  Anna S Nikonova; Igor Astsaturov; Ilya G Serebriiskii; Roland L Dunbrack; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

6.  Multimodal effects of small molecule ROCK and LIMK inhibitors on mitosis, and their implication as anti-leukemia agents.

Authors:  Yusuke Oku; Chiaki Tareyanagi; Shinichi Takaya; Sayaka Osaka; Haruki Ujiie; Kentaro Yoshida; Naoyuki Nishiya; Yoshimasa Uehara
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

7.  Latest progress in tyrosine kinase inhibitors.

Authors:  Tatiana V Pospelova; Valery A Pospelov
Journal:  Oncotarget       Date:  2014-03-15

8.  LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.

Authors:  A Petrilli; A Copik; M Posadas; L-S Chang; D B Welling; M Giovannini; C Fernández-Valle
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

9.  Maternal high-fat diet alters expression of pathways of growth, blood supply and arachidonic acid in rat placenta.

Authors:  Marloes Dekker Nitert; Kanchan Vaswani; Melissa Hum; Hsiu-Wen Chan; Ryan Wood-Bradley; Sarah Henry; James A Armitage; Murray D Mitchell; Gregory E Rice
Journal:  J Nutr Sci       Date:  2014-01-02

10.  Aurora A drives early signalling and vesicle dynamics during T-cell activation.

Authors:  Noelia Blas-Rus; Eugenio Bustos-Morán; Ignacio Pérez de Castro; Guillermo de Cárcer; Aldo Borroto; Emilio Camafeita; Inmaculada Jorge; Jesús Vázquez; Balbino Alarcón; Marcos Malumbres; Noa B Martín-Cófreces; Francisco Sánchez-Madrid
Journal:  Nat Commun       Date:  2016-04-19       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.